{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:56:11Z","timestamp":1792601771618,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27948-0","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T06:32:53Z","timestamp":1763793173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mesenchymal stromal cells in management of steroid refractory acute graft vesrus host disease, systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Mohammed","family":"Debes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harroop","family":"Athwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elyasaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouzeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaque","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Elantary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"27948_CR1","doi-asserted-by":"crossref","unstructured":"Ghimire, S., Weber, D., Mavin, E., Wang Xn, Dickinson, A. M. & Holler, E. Pathophysiology of GvHD and other HSCT-Related major complications. Front. Immunol. 8,\u00a079 (2017).","DOI":"10.3389\/fimmu.2017.00079"},{"issue":"7","key":"27948_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","volume":"53","author":"P Bader","year":"2018","unstructured":"Bader, P. et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transpl. 53 (7), 852\u2013862 (2018).","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"27948_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s44337-025-00382-x","volume":"2","author":"M Debes","year":"2025","unstructured":"Debes, M. et al. The JAK1\/2 inhibitor ruxolitinib as therapeutic option in steroid resistance, prophylaxis and frontline therapy for graft versus host disease, meta-analysis. Discover Med. 2 (1), 178 (2025).","journal-title":"Discover Med."},{"issue":"9624","key":"27948_CR4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (9624), 1579\u20131586 (2008).","journal-title":"Lancet"},{"issue":"1","key":"27948_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s44337-025-00191-2","volume":"2","author":"M Debes","year":"2025","unstructured":"Debes, M., Elyasaky, A., Elantary, R. & Abouzeid, M. Safety and efficacy of cellular therapy with mesenchymal stromal cells in sepsis, meta-analysis. Discover Med. 2 (1), 17 (2025).","journal-title":"Discover Med."},{"issue":"10","key":"27948_CR6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","volume":"81","author":"O Ringd\u00e9n","year":"2006","unstructured":"Ringd\u00e9n, O. et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (10), 1390\u20131397 (2006).","journal-title":"Transplantation"},{"issue":"9419","key":"27948_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (9419), 1439\u20131441 (2004).","journal-title":"Lancet"},{"issue":"2","key":"27948_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","volume":"103","author":"K Muroi","year":"2016","unstructured":"Muroi, K. et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study. Int. J. Hematol. 103 (2), 243\u2013250 (2016).","journal-title":"Int. J. Hematol."},{"issue":"10","key":"27948_CR9","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","volume":"56","author":"M Murata","year":"2021","unstructured":"Murata, M. et al. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplant. 56 (10), 2355\u20132366 (2021).","journal-title":"Bone Marrow Transplant."},{"key":"27948_CR10","doi-asserted-by":"publisher","first-page":"839844","DOI":"10.3389\/fimmu.2022.839844","volume":"13","author":"O Ringd\u00e9n","year":"2022","unstructured":"Ringd\u00e9n, O., Moll, G., Gustafsson, B. & Sadeghi, B. Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of Graft-Versus-Host Disease, hemorrhages and acute respiratory distress syndrome. Front. Immunol. 13, 839844 (2022).","journal-title":"Front. Immunol."},{"key":"27948_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"issue":"7","key":"27948_CR12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori, J. R., Norvell, D. C. & Chapman, J. R. Fixed-Effect vs Random-Effects models for Meta-Analysis: 3 points to consider. Global Spine J. 12 (7), 1624\u20131626 (2022).","journal-title":"Global Spine J."},{"issue":"2","key":"27948_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/eb-2014-101794","volume":"17","author":"A Nikolakopoulou","year":"2014","unstructured":"Nikolakopoulou, A., Mavridis, D. & Salanti, G. How to interpret meta-analysis models: fixed effect and random effects meta-analyses. Evid. Based Ment Health. 17 (2), 64 (2014).","journal-title":"Evid. Based Ment Health"},{"issue":"2","key":"27948_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina, T. B., S\u00e1nchez-Meca, J., Mar\u00edn-Mart\u00ednez, F. & Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods. 11 (2), 193\u2013206 (2006).","journal-title":"Psychol. Methods"},{"key":"27948_CR15","doi-asserted-by":"crossref","unstructured":"Fekete, J. T. & Gy\u0151rffy, B. MetaAnalysisOnline.com: an online tool for the rapid Meta-Analysis of clinical and epidemiological studies. J. Med. Int. Res. 27, e64016 (2025).","DOI":"10.2196\/64016"},{"key":"27948_CR16","doi-asserted-by":"crossref","unstructured":"Sterne, J. A. C. H. M., McAleenan, A., Reeves, B. C. & Higgins, J. P. T. Assessing risk of bias in a non-randomized study, from: Cochrane handbook of systematic reviews and interventions (2019). https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-25","DOI":"10.1002\/9781119536604.ch25"},{"key":"27948_CR17","doi-asserted-by":"crossref","unstructured":"McGuinness, L. A. & Higgins, J. P. T. Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res. Synthesis Method. (2020).","DOI":"10.1002\/jrsm.1411"},{"issue":"6","key":"27948_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli, G. M. et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 52 (6), 859\u2013862 (2017).","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"27948_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","volume":"21","author":"K Zhao","year":"2015","unstructured":"Zhao, K. et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 21 (1), 97\u2013104 (2015).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"4","key":"27948_CR20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/bmt.2016.317","volume":"52","author":"U Salmenniemi","year":"2017","unstructured":"Salmenniemi, U. et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transpl. 52 (4), 606\u2013608 (2017).","journal-title":"Bone Marrow Transpl."},{"issue":"10","key":"27948_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser, R. et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29 (10), 2062\u20132068 (2015).","journal-title":"Leukemia"},{"issue":"10","key":"27948_CR22","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","volume":"20","author":"F S\u00e1nchez-Guijo","year":"2014","unstructured":"S\u00e1nchez-Guijo, F. et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol. Blood Marrow Transpl. 20 (10), 1580\u20131585 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"2","key":"27948_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/stem.2224","volume":"34","author":"F von Dalowski","year":"2016","unstructured":"von Dalowski, F. et al. Mesenchymal stromal cells for treatment of acute Steroid-Refractory graft versus host disease: clinical responses and Long-Term outcome. Stem Cells. 34 (2), 357\u2013366 (2016).","journal-title":"Stem Cells"},{"issue":"11","key":"27948_CR24","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/bmt.2017.177","volume":"52","author":"C Fern\u00e1ndez-Maqueda","year":"2017","unstructured":"Fern\u00e1ndez-Maqueda, C. et al. Mesenchymal stromal cells for steroid-refractory acute GvHD. Bone Marrow Transplant. 52 (11), 1577\u20131579 (2017).","journal-title":"Bone Marrow Transplant."},{"issue":"29","key":"27948_CR25","doi-asserted-by":"publisher","first-page":"20590","DOI":"10.18632\/oncotarget.25020","volume":"9","author":"S Servais","year":"2018","unstructured":"Servais, S. et al. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. Oncotarget 9 (29), 20590\u201320604 (2018).","journal-title":"Oncotarget"},{"issue":"5","key":"27948_CR26","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","volume":"26","author":"P Kebriaei","year":"2020","unstructured":"Kebriaei, P. et al. A phase 3 randomized study of Remestemcel-L versus placebo added to Second-Line therapy in patients with Steroid-Refractory acute Graft-versus-Host disease. Biol. Blood Marrow Transpl. 26 (5), 835\u2013844 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"4","key":"27948_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/stcltm\/szac003","volume":"11","author":"MDM Mac\u00edas-S\u00e1nchez","year":"2022","unstructured":"Mac\u00edas-S\u00e1nchez, M. D. M. et al. Mesenchymal stromal cells for treating Steroid-Resistant acute and chronic graft versus host disease: A multicenter compassionate use experience. Stem Cells Transl Med. 11 (4), 343\u2013355 (2022).","journal-title":"Stem Cells Transl Med."},{"issue":"1","key":"27948_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao, K. et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J. Hematol. Oncol. 15 (1), 22 (2022).","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"27948_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12967-023-04731-1","volume":"21","author":"H Bonig","year":"2023","unstructured":"Bonig, H. et al. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells Preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease. J. Transl Med. 21 (1), 837 (2023).","journal-title":"J. Transl Med."},{"issue":"6","key":"27948_CR30","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00277-023-05216-3","volume":"102","author":"M Keklik","year":"2023","unstructured":"Keklik, M. et al. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 102 (6), 1537\u20131547 (2023).","journal-title":"Ann. Hematol."},{"issue":"2","key":"27948_CR31","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","volume":"16","author":"PJ Martin","year":"2010","unstructured":"Martin, P. J. et al. Prochymal improves response rates in patients with Steroid-Refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of A Randomized, Placebo-Controlled, multicenter phase III trial in GVHD. Biol. Blood Marrow Transplant. 16 (2), S169\u2013S70 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"27948_CR32","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","volume":"3","author":"S Hashmi","year":"2016","unstructured":"Hashmi, S. et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 3 (1), e45\u2013e52 (2016).","journal-title":"Lancet Haematol."},{"issue":"10","key":"27948_CR33","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg, E. et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem Cells Transl Med. 9 (10), 1190\u20131202 (2020).","journal-title":"Stem Cells Transl Med."},{"issue":"3","key":"27948_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mvr.2009.02.001","volume":"77","author":"D Furlani","year":"2009","unstructured":"Furlani, D. et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc. Res. 77 (3), 370\u2013376 (2009).","journal-title":"Microvasc. Res."},{"issue":"7","key":"27948_CR35","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.transproceed.2017.03.078","volume":"49","author":"Z Wu","year":"2017","unstructured":"Wu, Z. et al. Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: A report of two cases and literature review. Transpl. Proc. 49 (7), 1656\u20131658 (2017).","journal-title":"Transpl. Proc."},{"issue":"7","key":"27948_CR36","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","volume":"15","author":"L Barkholt","year":"2013","unstructured":"Barkholt, L. et al. Risk of tumorigenicity in mesenchymal stromal cell\u2013based therapies\u2014Bridging scientific observations and regulatory viewpoints. Cytotherapy 15 (7), 753\u2013759 (2013).","journal-title":"Cytotherapy"},{"issue":"1","key":"27948_CR37","first-page":"Cd009768","volume":"1","author":"SA Fisher","year":"2019","unstructured":"Fisher, S. A. et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in Haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst. Rev. 1 (1), Cd009768 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"27948_CR38","doi-asserted-by":"publisher","first-page":"119284","DOI":"10.1016\/j.biomaterials.2019.119284","volume":"217","author":"MT Ghorbel","year":"2019","unstructured":"Ghorbel, M. T. et al. Reconstruction of the pulmonary artery by a novel biodegradable conduit engineered with perinatal stem cell-derived vascular smooth muscle cells enables physiological vascular growth in a large animal model of congenital heart disease. Biomaterials 217, 119284 (2019).","journal-title":"Biomaterials"},{"key":"27948_CR39","unstructured":"Debes, M. Stem Cells and Regenerative Medicine for Congenital Heart Disease (University of Bristol, 2021)."},{"issue":"1","key":"27948_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13287-019-1287-9","volume":"10","author":"L Zhao","year":"2019","unstructured":"Zhao, L., Chen, S., Yang, P., Cao, H. & Li, L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell. Res. Ther. 10 (1), 182 (2019).","journal-title":"Stem Cell. Res. Ther."},{"issue":"1","key":"27948_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13287-021-02170-7","volume":"12","author":"R Li","year":"2021","unstructured":"Li, R. et al. Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis. Stem Cell. Res. Ther. 12 (1), 106 (2021).","journal-title":"Stem Cell. Res. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27948-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:25:21Z","timestamp":1766147121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27948"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27948-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44196"}}